Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Prevents severely restricted mobility during acute illness Inpatient treatment of acute…. Sold as Lovenox. Every FDA application for this active ingredient: 2 branded and 11 generic.
As of Nov 15, 2026, FDA lists 13 applications for Enoxaparin Sodium (sold as Lovenox), first approved Mar 29, 1993, with 8 new uses approved and 0 published complete response letters.
First approved: Mar 29, 1993
Applications: 13
New uses approved: 8
Complete response letters: 0
Medicare spending, 2025: $78.3M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
ClexaneA drug with a new additional indication for prophylaxis of venous thromboembolism in patients undergoing abdominal surgery who are at a high risk of… · Sanofi-Aventis K.K. · Feb 23, 2009
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sanofi Aventis US
Sandoz
Zydus Pharms